NUDT2

Across TCGA pan-cancer cohorts, NUDT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NUDT2 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NUDT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NUDT2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where NUDT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.564	0.807	.005	13	view →
LUAD	OS	Tertile	All	0.595	0.835	.024	11	view →
PDAC	OS	Quartile	All	0.706	0.485	.018	6	view →
UCEC	OS	Median	All	1.000	0.904	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NUDT2–HNSC (OS)

Open the HNSC breakdown →